美国风湿病学会RISE注册研究中接受长期降尿酸治疗的痛风患者血尿酸监测与达标情况
基于美国风湿病学会RISE注册研究,纳入2018—2019年确诊痛风且持续使用降尿酸治疗≥12个月的9560例患者,评估血尿酸监测比例及达标(<6.0 mg/dl)情况。56%的患者在测量年内至少记录1次血尿酸,其中74%达到目标值;非白人患者检测或达标的可能性略低。
要点
- 接受长期降尿酸治疗且由风湿科医生纵向随访的痛风患者中,56%在测量年内至少记录1次血尿酸。
- 在至少记录1次血尿酸的患者中,74%达到血尿酸<6.0 mg/dl的目标。
- 多变量分析中,非白人患者接受检测或达到目标血尿酸的可能性略低。
核心结论
- 在接受长期降尿酸治疗并由风湿科医生纵向随访的痛风患者中,超过半数有血尿酸记录,而在受检者中四分之三达到推荐的血尿酸目标。
- 作者认为,常规监测血尿酸是改善痛风患者照护质量的第一步。
研究设计与样本
- 基于美国风湿病学会RISE注册研究的分析,纳入2018—2019年有一条或以上痛风诊断且持续使用降尿酸治疗≥12个月的患者。
- 共纳入9560例患者,平均±标准差年龄为67.2±12.7岁,73.5%为男性,32.3%为非白人。
- 采用多水平logistic回归调整社会人口学特征、合并症、地区和医疗服务利用情况,以确定与血尿酸监测及达标相关的因素。
主要发现
- 56%的患者在测量年内至少记录1次血尿酸。
- 在至少记录1次血尿酸的患者中,74%达到血尿酸<6.0 mg/dl的目标。
- 多变量分析中,非白人患者接受检测或达到目标血尿酸的可能性略低。
关键数值与推荐
- 美国风湿病学会2020年痛风管理指南推荐采用达标治疗策略降低血尿酸。
- 本研究中达标定义为血尿酸<6.0 mg/dl。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The American College of Rheumatology's (ACR) 2020 guidelines for the management of gout recommend using a treat-to-target approach to lower serum urate (SU). Using the ACR's Rheumatology Informatics System for Effectiveness registry, we examined the use of a treat-to-target approach among gout patients receiving long-term urate-lowering therapy (ULT) and followed longitudinally by rheumatologists. METHODS: Included patients had one or more diagnoses for gout in 2018-2019 and continuous use of ULT for ≥12 months. We assessed the proportions of patients with SU monitoring and, among those tested, who achieved SU <6.0 mg/dl during the measurement year. Multilevel logistic regression adjusting for sociodemographics, comorbidities, region, and health care utilization was used to determine factors associated with SU monitoring and achievement of target SU. RESULTS: A total of 9,560 were included. The mean ± SD age was 67.2 ± 12.7 years, 73.5% of patients were male, and 32.3% were non-White. Fifty-six percent of patients had at least 1 SU recorded during the measurement year; among patients with at least 1 SU recorded, 74% achieved the SU target. In multivariate analyses, non-White patients were slightly less likely to be tested or achieve a target SU. CONCLUSION: Among gout patients receiving long-term ULT followed longitudinally by rheumatologists, more than half had a documented SU, and among those tested, three-quarters achieved the recommended SU target. Routine monitoring of SU is a first step toward improving quality of care for patients with gout.
引用
- Hammam N, Li J, Kay J, et al. Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry. Arthritis Care Res (Hoboken). 2023. PMID: 36039961. doi:10.1002/acr.25009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。